Table 3.

Current clinical trials addressed with nanoparticles for the treatment of neurodegenerative diseases

Name	NP type	Application	Clinical trial
APH-1105	Lipid nanoparticles	Alzheimer Disease	NCT03806478; Phase 2; Not yet recruiting
CNM-Au8	Gold nanocrystals	Amyotrophic Lateral Sclerosis	NCT04098406; Phase 2; Completed
CNM-Au8	Gold nanocrystals	Parkinson's Disease	NCT03815916; Phase 2; Completed
CNM-Au8	Gold nanocrystals	Amyotrophic Lateral Sclerosis	NCT04081714; Available
NTLA-2001	Lipid nanoparticles	Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy Wild-Type Transthyretin Cardiac Amyloidosis	NCT0460105; Active; Phase;1 not recruiting
CNM-Au8	Gold nanocrystals	Amyotrophic Lateral Sclerosis	NCT03843710; Phase 2; Withdrawn
Chitosan Phonophoresis	Chitosan nanoparticles gel	Device: Chitosan Phonophoresis Device: Therapeutic Ultrasound Device: Splinting Other: Neural mobilization exercises of the ulnar nerve	NCT05212311; Not Applicable; Completed